Skip to main content
S&P 5007,666.45+0.19%DOW50,926.56+0.04%NASDAQ26,871.60+0.04%BTC$84,606.00+1.09%ETH$2,697.90+0.59%GOLD$4,207.20+0.49%OIL$92.87+2.71%
Smart Investors Daily
SID Premium
ST

NASDAQ · STTK

Shattuck Labs, Inc.

Healthcare · Biotechnology

$6.82

Up+$0.15 (+2.14%)

Updated Oct 1, 2026, 7:38 PM

SID Score

5.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
154.73M
P/E ratio
-4.25
Dividend yield
0.00%
52-week range
$1.70 – $8.33
Volume
3.36M
Avg. volume
297.21K

Price performance · STTK

STTK price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Sep 30, 2026

STTK closed at $6.82 after 20 trading sessions, down 1.30% for the selected period.

Last close
$6.82
Period change
-1.30%
Period low
$5.85
Period high
$6.96
Daily close
View OHLC price history
STTK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 30, 2026$6.64$7.42$6.52$6.823.36M
Sep 29, 2026$6.43$6.635$6.32$6.54956.83K
Sep 28, 2026$6.03$6.48$5.85$6.43976.89K
Sep 25, 2026$6.33$6.3867$6.045$6.07893.67K
Sep 24, 2026$6.34$6.40$6.00$6.311.43M
Sep 23, 2026$6.47$6.61$6.265$6.361.39M
Sep 22, 2026$6.20$6.54$6.10$6.501.46M
Sep 21, 2026$6.09$6.21$5.86$6.111.04M
Sep 18, 2026$5.86$6.215$5.80$6.017.4M
Sep 17, 2026$6.03$6.095$5.80$5.85654.38K
Sep 16, 2026$6.00$6.12$5.78$5.88743.06K
Sep 15, 2026$6.18$6.23$5.911$5.97895.24K
Sep 14, 2026$6.21$6.265$6.085$6.20821.91K
Sep 11, 2026$6.24$6.36$6.07$6.20846.93K
Sep 10, 2026$6.21$6.345$6.10$6.151.17M
Sep 9, 2026$6.39$6.57$6.245$6.331.06M
Sep 8, 2026$6.80$6.86$6.47$6.501M
Sep 4, 2026$6.84$6.88$6.6742$6.79677.76K
Sep 3, 2026$6.96$7.045$6.83$6.96563.93K
Sep 2, 2026$6.91$7.28$6.77$6.91583.53K

Latest STTK news

The latest Smart Investors Daily articles mentioning STTK.

Stock researchCompany · Overview

STTK research

Overview

Company profile and research snapshot.

Company profile

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$4.00
Implied upside
—
Analysts
12
STTK recent ratings
DateFirmRatingTarget
Aug 24, 2026Raymond JamesStrong Buy—
Aug 11, 2026HC Wainwright & Co.Buy—
Jul 24, 2026JP MorganOverweight—
Jul 20, 2026Leerink PartnersOutperform—
Jun 9, 2026CitigroupBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 2, 2026

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences: Conference Details Wells Farg

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By